149 related articles for article (PubMed ID: 35830231)
21. Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides.
Wang S; Sun H; Tanowitz M; Liang XH; Crooke ST
Nucleic Acids Res; 2017 May; 45(9):5309-5322. PubMed ID: 28379543
[TBL] [Abstract][Full Text] [Related]
22. Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs.
Takakusa H; Iwazaki N; Nishikawa M; Yoshida T; Obika S; Inoue T
Nucleic Acid Ther; 2023 Apr; 33(2):83-94. PubMed ID: 36735616
[TBL] [Abstract][Full Text] [Related]
23. Phospholamban Inhibition by a Single Dose of Locked Nucleic Acid Antisense Oligonucleotide Improves Cardiac Contractility in Pressure Overload-Induced Systolic Dysfunction in Mice.
Morihara H; Yamamoto T; Oiwa H; Tonegawa K; Tsuchiyama D; Kawakatsu I; Obana M; Maeda M; Mohri T; Obika S; Fujio Y; Nakayama H
J Cardiovasc Pharmacol Ther; 2017 May; 22(3):273-282. PubMed ID: 27811197
[TBL] [Abstract][Full Text] [Related]
24. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.
Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW
J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271
[TBL] [Abstract][Full Text] [Related]
25. Distribution and biotransformation of therapeutic antisense oligonucleotides and conjugates.
Weidolf L; Björkbom A; Dahlén A; Elebring M; Gennemark P; Hölttä M; Janzén D; Li X; Andersson S
Drug Discov Today; 2021 Oct; 26(10):2244-2258. PubMed ID: 33862193
[TBL] [Abstract][Full Text] [Related]
26. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
[TBL] [Abstract][Full Text] [Related]
27. Cholesterol-GalNAc Dual Conjugation Strategy for Reducing Renal Distribution of Antisense Oligonucleotides.
Wada F; Yamamoto T; Ueda T; Sawamura M; Wada S; Harada-Shiba M; Obika S
Nucleic Acid Ther; 2018 Feb; 28(1):50-57. PubMed ID: 29360004
[TBL] [Abstract][Full Text] [Related]
28. Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes.
Kinberger GA; Prakash TP; Yu J; Vasquez G; Low A; Chappell A; Schmidt K; Murray HM; Gaus H; Swayze EE; Seth PP
Bioorg Med Chem Lett; 2016 Aug; 26(15):3690-3. PubMed ID: 27268307
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive Structure-Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes.
Prakash TP; Yu J; Migawa MT; Kinberger GA; Wan WB; Østergaard ME; Carty RL; Vasquez G; Low A; Chappell A; Schmidt K; Aghajan M; Crosby J; Murray HM; Booten SL; Hsiao J; Soriano A; Machemer T; Cauntay P; Burel SA; Murray SF; Gaus H; Graham MJ; Swayze EE; Seth PP
J Med Chem; 2016 Mar; 59(6):2718-33. PubMed ID: 26914862
[TBL] [Abstract][Full Text] [Related]
30. Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.
Yu RZ; Gunawan R; Post N; Zanardi T; Hall S; Burkey J; Kim TW; Graham MJ; Prakash TP; Seth PP; Swayze EE; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2016 Dec; 26(6):372-380. PubMed ID: 27500733
[TBL] [Abstract][Full Text] [Related]
31. Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Migliorati JM; Liu S; Liu A; Gogate A; Nair S; Bahal R; Rasmussen TP; Manautou JE; Zhong XB
Drug Metab Dispos; 2022 Jun; 50(6):888-897. PubMed ID: 35221287
[TBL] [Abstract][Full Text] [Related]
32. COPII vesicles can affect the activity of antisense oligonucleotides by facilitating the release of oligonucleotides from endocytic pathways.
Liang XH; Sun H; Nichols JG; Allen N; Wang S; Vickers TA; Shen W; Hsu CW; Crooke ST
Nucleic Acids Res; 2018 Nov; 46(19):10225-10245. PubMed ID: 30239896
[TBL] [Abstract][Full Text] [Related]
33. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
[TBL] [Abstract][Full Text] [Related]
34. The nuclear concentration required for antisense oligonucleotide activity in myotonic dystrophy cells.
van der Bent ML; Paulino da Silva Filho O; Willemse M; Hällbrink M; Wansink DG; Brock R
FASEB J; 2019 Oct; 33(10):11314-11325. PubMed ID: 31311315
[TBL] [Abstract][Full Text] [Related]
35. Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides.
Bailey JK; Shen W; Liang XH; Crooke ST
Nucleic Acids Res; 2017 Oct; 45(18):10649-10671. PubMed ID: 28977508
[TBL] [Abstract][Full Text] [Related]
36. Identification of GalNAc-Conjugated Antisense Oligonucleotide Metabolites Using an Untargeted and Generic Approach Based on High Resolution Mass Spectrometry.
Husser C; Brink A; Zell M; Müller MB; Koller E; Schadt S
Anal Chem; 2017 Jun; 89(12):6821-6826. PubMed ID: 28520401
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc
Wang Y; Yu RZ; Henry S; Geary RS
Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):475-485. PubMed ID: 31144994
[No Abstract] [Full Text] [Related]
38. Improved Cellular Delivery of Antisense Oligonucleotide for miRNA-21 Imaging In Vivo Using Cell-Penetrating Peptide-Based Nanoprobes.
Yang G; Zhao Y; Gong A; Miao W; Yan L; Nie P; Wang Z
Mol Pharm; 2021 Mar; 18(3):787-795. PubMed ID: 33480702
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
[TBL] [Abstract][Full Text] [Related]
40. Perturbing the Normal Level of SIDT1 Suppresses the Naked ASO Effect.
Takahashi M; Seki M; Nashimoto M; Kabuta T
J Nucleic Acids; 2021; 2021():2458470. PubMed ID: 34824869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]